Physician profile
Jeffrey Kim
NPI 1457679631
$13,019.93
in general payments reported to CMS, 2019-2025
56 companies · $2,434 in 2025
The $2,434 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,369 · 2020: $996 · 2021: $1,355 · 2022: $1,883 · 2023: $2,020 · 2024: $1,964 · 2025: $2,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,273 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,273.32 |
| Education | $144.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,129.63 | 2019-2025 | |
| Abbvie INC. | $1,901.52 | 2021-2025 | |
| Lilly USA, LLC | $696.08 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biogen, INC. | $634.03 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Ucb, INC. | $571.59 | 2019-2025 | Briviact, Nayzilam |
| Amgen INC. | $563.51 | 2019-2025 | Uplizna, Aimovig |
| Csl Behring | $547.60 | 2019-2025 | Hizentra |
| Mdd US Operations, LLC | $405.94 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Alexion Pharmaceuticals, INC. | $370.94 | 2019-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $335.21 | 2019-2025 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $325.58 | 2019-2025 | Crexont, Rytary |
| Argenx US, INC. | $287.74 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $282.81 | 2021-2025 | Vyepti, Rexulti |
| Celgene Corporation | $280.45 | 2022-2025 | Zeposia |
| Genzyme Corporation | $275.50 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.